Saturday, June 24, 2006 9:14:48 PM
Re: rfoable1 ,more 4 patient trials by: rfoable1 06/24/06 08:54 pm
Msg: 110324 of 110324
docmo,
In answer to your query in the final line of your post - I'm betting "Answer B":
"...just to realize misconceptions about whats really on the forefront of insulin resistance."
I'm not sure whether your're being a flaming sarcastic, or whether you are seriously pointing out that almost all big ideas start with tiny proof-of-concept experiments.
In fact the newest Byetta combination work looks quite exciting. But beware! There are folks out here on the MB that don't want to hear about tiny, early, preliminary results.
Combine Byetta with islet cell infusions in several small 4 patient cohorts and have the nerve to actually present that as science!!?? Ridiculous!! Must be shameless Amylin & Lilly pumpers!
Luckily the MB sceptics are not running medical research units or R&D departments in pharmas - because if they were, no really innovative new approaches would get anywhere.
Its amazing to me that the underlying potent insulin sensitization which Iplex provides is not recognized by some. The various poster presentations, abstracts and statements by Insmed all point to a set of uses both in patients needing exogenous insulin and in those who may not.
Another thing about the Byetta approval - insmterry might note that the primary clinical endpoint for the FDA approval was - guess what! - HbA1c reduction at 30 weeks. After all that hoopla about how FDA supposedly changed all its thinking - the "new paradigm" etc. where tracking of HbA1c was dismissed as simplistic...
I'm not worried about any of it. There's plenty of room for insulin, Byetta pens, Symlin, islet cells, other GLP-1 mimetics, Iplex etc in diabetic treatment paradigms. Everyone will find their niche and, as usual, anything that actually WORKS will endure and prosper.
I actually appreciate the thoughful summary of "what's happening" out there on the cutting edge. Good science always wins in the end, which is why I'm long on INSM.
peace.
http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=1600811390&tid=insm&sid=....
Msg: 110324 of 110324
docmo,
In answer to your query in the final line of your post - I'm betting "Answer B":
"...just to realize misconceptions about whats really on the forefront of insulin resistance."
I'm not sure whether your're being a flaming sarcastic, or whether you are seriously pointing out that almost all big ideas start with tiny proof-of-concept experiments.
In fact the newest Byetta combination work looks quite exciting. But beware! There are folks out here on the MB that don't want to hear about tiny, early, preliminary results.
Combine Byetta with islet cell infusions in several small 4 patient cohorts and have the nerve to actually present that as science!!?? Ridiculous!! Must be shameless Amylin & Lilly pumpers!
Luckily the MB sceptics are not running medical research units or R&D departments in pharmas - because if they were, no really innovative new approaches would get anywhere.
Its amazing to me that the underlying potent insulin sensitization which Iplex provides is not recognized by some. The various poster presentations, abstracts and statements by Insmed all point to a set of uses both in patients needing exogenous insulin and in those who may not.
Another thing about the Byetta approval - insmterry might note that the primary clinical endpoint for the FDA approval was - guess what! - HbA1c reduction at 30 weeks. After all that hoopla about how FDA supposedly changed all its thinking - the "new paradigm" etc. where tracking of HbA1c was dismissed as simplistic...
I'm not worried about any of it. There's plenty of room for insulin, Byetta pens, Symlin, islet cells, other GLP-1 mimetics, Iplex etc in diabetic treatment paradigms. Everyone will find their niche and, as usual, anything that actually WORKS will endure and prosper.
I actually appreciate the thoughful summary of "what's happening" out there on the cutting edge. Good science always wins in the end, which is why I'm long on INSM.
peace.
http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=1600811390&tid=insm&sid=....
Recent INSM News
- Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026 • PR Newswire (US) • 04/23/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/17/2026 08:43:36 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/16/2026 08:17:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:41:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 08:01:21 PM
- Insmed Provides Clinical Update on Phase 2b CEDAR Study • PR Newswire (US) • 04/07/2026 08:01:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/06/2026 08:42:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:07:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 09:10:46 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/01/2026 08:03:54 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/01/2026 08:02:49 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/01/2026 08:01:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 08:13:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/30/2026 09:31:03 PM
- Insmed shares rise after UTHR trial data and Morgan Stanley upgrade • IH Market News • 03/30/2026 03:04:13 PM
- Insmed shares rise on positive results from ARIKAYCE Phase 3b study • IH Market News • 03/23/2026 02:34:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 11:00:30 AM
- Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease • PR Newswire (US) • 03/23/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:05:20 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/19/2026 08:57:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2026 09:59:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:16:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:15:10 PM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 03/05/2026 12:00:00 PM

